DECEMBER - MARCH19TECH OUTLOOKservices offer tailor-made media formulations for large-scale production and procurement. JSBio customizes cell culture media to fit clients' specific project needs, providing bespoke media and supplements for batch, fed-batch, and perfusion applications. This ensures maximum product yield and quality for various cell lines, including CHO, HEK293, Vero, Sf9/SF21, MDCK, etc., helping clients achieve superior platform performance, dependable product supply, and cost efficiency while mitigating supply chain risks.Delivering Customer-Focused Cell Culture Process and Technical ServicesWith a `customer-focused' approach, JSBio prioritizes prompt, round-the-clock responsiveness and collaborations to ensure customer success. In cell culture process development, the company provides full services in the JSBio laboratory, and semi-contracted services in clients' laboratories. Other services include customized media formulation, formula components, media form, packaging specifications, and inspection items.JSBio currently operates in Haimen, Shanghai, Lanzhou (China), South Korea, and the U.S. to meet the global demands for biologic drugs. Its manufacturing facilities are equipped with state-of-the-art production equipment, and the company adheres to GMP compliance to ensure world-class standards. The company has implemented standardized and harmonized processes, raw materials, and qualifications across all sites, providing customers with manufacturing flexibility.The capacity to produce large quantities of media gives JSBio a competitive edge in serving the rapidly growing biopharmaceutical markets. By incorporating customized design, JSBio has achieved an advanced production process. For example, the company's production line incorporates built-in temperature regulation monitoring and explosion prevention mechanisms, alongside humidity and oxidation control systems. These features are crucial to processing a broader spectrum of media with enhanced precision and safety. Also, control over residence time in the mill ensures particles are reduced to the desired size while maintaining optimal efficiency.For example, JSBio's R&D team collaborated with a Covid-19 vaccine company in 2021. By optimizing technologies and processes, the collaboration resulted in a 17-fold increase in vaccine production, significantly accelerating commercial processes.Establishing Long-Term PartnershipsBy offering different types of media, JSBio demonstrates flexibility in meeting client preferences and process requirements. For example, when meeting scientific research clients who require a small quantity of pre-configured liquid culture medium, the company provides liquid culture medium products within a quick turnaround time of 2-3 weeks. On the other hand, industrial clients typically have a high demand for large quantities of culture media, often exceeding 2000L. To accommodate their transportation and storage needs, JSBio rapidly produces dry powder media and arranges corresponding logistics for efficient delivery."We pride ourselves on our industry-leading lead time of 30-45 days, ensuring a seamless transition from small to large scales with our flexible dry powder capacity. Our lot-to-lot consistency guarantees reliable and consistent product quality," says Dr. Luo.JSBio adheres to a compliance system that meets customer regulatory expectations. This helps to decrease the customer's burden on upstream processes for clients. Long-term partnerships with over 500 biopharmaceutical companies and research institutes have also contributed to the successful launch of hundreds of antibody and vaccine products. "As the industry evolves, we stand to lead the charge in innovative cell culture solutions, setting new benchmarks for excellence and reliability," says Dr. Luo. The protein expression levels achieved by the customized cell culture media we develop for our clients significantly surpass and outstrip their expectations
< Page 9 | Page 11 >